Therefore, additional genetic alterations are necessary to allow MYC to exert its oncogenic activity in cancer cells, e.g., the enhanced expression of antiapoptotic factors such as BCL2 (through chromosomal translocations) or mutations in checkpoint genes like TP53 [42] (Figure 1). This evidence concerns the gene TP53 and cancer.